Company intelligence / Profile preview

XYROKINETICS

South San Francisco, CA, USA

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors for debilitating diseases characterized by impaired muscle function, including cardiovascular diseases like heart failure and hypertrophic cardiomyopathy, and neuromuscular diseases like ALS. They have multiple programs in late-stage clinical development and one approved product (Omecamtiv Mecarbil) in Japan for chronic heart failure.

Therapeutic areas: CardiovascularNeurology
Modalities: Small MoleculeMuscle ActivatorsMuscle Inhibitors
Industry: Biotech

Partnerships

Astellas Pharma (for Omecamtiv Mecarbil in Japan)

Beyond the preview

Go deeper on XYROKINETICS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYROKINETICS.

Explore the full profile